Natalizumab in the treatment of Crohn's disease.
The pathogenesis of Crohn's disease (CD) is multifactorial and the activation of specific pathways of immunological system is important. In particular, the adhesion molecules (integrins) mediate the selective binding between the leukocytes and the endothelial cells regulating the migration of leukocytes into the normal and inflamed intestine. Selective adhesion molecule inhibitors interfere with the migration of leukocytes to the sites of inflammation by targeting adhesion molecules (alpha4-integrin or alpha4beta7-integrin). Natalizumab is a humanized IgG4 anti-alpha4-integrin monoclonal antibody that inhibits both alpha4beta7-integrin/mucosal addressin-cell adhesion molecule-1 (MadCAM-1) interaction and alpha4beta1/vascular-cell adhesion molecule-1 (VCAM-1) binding. Pooled data from the four studies, analyzed in a Cochrane review, suggest that natalizumab is effective for induction of clinical response and remission in patients with moderately to severely active CD. In particular, natalizumab may be beneficial for patients with active inflammation or chronically active disease despite the use of conventional therapies with high level of C-reactive protein values at baseline time. Nevertheless, many problems about the utilization of natalizumab in CD remain unsolved (such as the high placebo response, the final definition of dosage and timing schedule, the definition of outcomes and the development of adverse events).
Guagnozzi
Danila
D
Gastroenterology Unit, Department of Clinical Sciences, University of Rome "La Sapienza", Rome, Italy.
Caprilli
Renzo
R
Gastroenterology. 1996 Nov;111(5):1373-80
8898653
J Immunol. 1997 Mar 1;158(5):2099-106
9036954
N Engl J Med. 2003 Jan 2;348(1):15-23
12510038
Aliment Pharmacol Ther. 2002 Apr;16(4):699-705
11929387
Cell. 1994 Jan 28;76(2):301-14
7507411
J Clin Invest. 1993 Jul;92(1):372-80
7686922
N Engl J Med. 2005 Jul 28;353(4):375-81
15947078
Curr Opin Gastroenterol. 2007 Jul;23(4):395-9
17545775
Nature. 1992 Mar 5;356(6364):63-6
1538783
Cell. 1995 Feb 10;80(3):413-22
7532110
Lab Invest. 2000 Oct;80(10):1541-51
11045571
N Engl J Med. 2005 Nov 3;353(18):1965-8
16267329
Genes Dev. 1995 Aug 1;9(15):1883-95
7544312
Gastroenterology. 1990 Apr;98(4):811-8
2179031
World J Gastroenterol. 2006 Aug 7;12(29):4628-35
16937430
N Engl J Med. 2000 Oct 5;343(14):1020-34
11018170
Gastroenterology. 2001 Aug;121(2):268-74
11487536
N Engl J Med. 2005 Jul 28;353(4):414-6
15947082
N Engl J Med. 2005 Jul 28;353(4):362-8
15947080
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006097
17253580
N Engl J Med. 2005 Jul 28;353(4):369-74
15947079
N Engl J Med. 2006 Mar 2;354(9):924-33
16510746
N Engl J Med. 2003 Jan 2;348(1):24-32
12510039
J Cell Biol. 1995 Mar;128(6):1243-53
7534768
Cell. 2002 Sep 20;110(6):673-87
12297042
N Engl J Med. 2005 Nov 3;353(18):1912-25
16267322
Lancet. 1998 Nov 28;352(9142):1742-6
9848350
N Engl J Med. 2005 Jul 28;353(4):432-3
15947083
Gastroenterology. 2007 May;132(5):1672-83
17484865
Gastroenterology. 1998 Jul;115(1):182-205
9649475
Anticancer Res. 2005 Mar-Apr;25(2A):1079-85
15868949
FASEB J. 1995 Aug;9(11):1103-11
7544310
Science. 1996 Apr 5;272(5258):60-6
8600538
Am J Transplant. 2005 Mar;5(3):582-94
15707414
Curr Opin Gastroenterol. 2005 Jan;21(1):85-9
15687890